{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:01:34Z","timestamp":1790740894182,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T00:00:00Z","timestamp":1675641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82171453"],"award-info":[{"award-number":["82171453"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of\u00a0Hunan Province","doi-asserted-by":"publisher","award":["2021JJ30393"],"award-info":[{"award-number":["2021JJ30393"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014215","name":"Huxiang Youth Talent Support Program","doi-asserted-by":"publisher","award":["2021RC3117"],"award-info":[{"award-number":["2021RC3117"]}],"id":[{"id":"10.13039\/501100014215","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Key projects supported by Hunan Provincial Health Commission","award":["202203074966"],"award-info":[{"award-number":["202203074966"]}]},{"name":"Scientific research projects of Hunan Health Committee","award":["2017SK50704, 2108TP1028"],"award-info":[{"award-number":["2017SK50704, 2108TP1028"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>To strengthen the understanding of the clinical features for CASPR2 neurological autoimmunity in children. A multicenter retrospective and prospective analysis of CASPR2 autoimmunity was conducted. Twenty-six patients were enrolled, including 25 with serum positivity and 3 with cerebrospinal fluid (CSF) positivity; 5 patients were co-positive with anti-NMDAR or anti-GABABR antibodies. Eleven patients (who manifested with refractory epilepsy, psychobehavioral abnormalities or germinoma) presented with low antibody titers, relatively normal MRI\/EEG\/CSF examinations, and poor response to immunotherapy and were thus considered false positive (42.3%). Fifteen patients were diagnosed with autoimmune encephalitis\/ encephalopathy\/ cerebellitis (including 1 whose condition was secondary to Japanese encephalitis). The most common symptoms included disorders of consciousness (10\/15), fever (8\/15), psychological symptoms\/abnormal behaviors (8\/15), sleep disorders (8\/15), seizures (7\/15), movement disorders (5\/15), autonomic symptoms (5\/15). Brain MRI revealed abnormalities in 10 patients (66.7%). Electroencephalography (EEG) recordings revealed a slow wave background in 13 patients (86.7%). Five patients showed elevated WBCs in CSF, and 4 patients showed elevated protein levels in the CSF. Thirteen patients received immunotherapy (rituximab was adopted in 2 cases) and recovered well. Two patients received symptomatic treatment, and the recovery was slow and accompanied by emotional abnormalities and developmental delay. Autoimmune encephalitis is the most common clinical phenotype; it can be secondary to Japanese encephalitis. Rituximab can be used in patients who respond poorly to conventional immunotherapy. The high false-positive rate of anti-CASPR2 in refractory epilepsy and the psychobehavioral abnormalities needs to be explored further.<\/jats:p>","DOI":"10.1038\/s41598-023-28268-x","type":"journal-article","created":{"date-parts":[[2023,2,6]],"date-time":"2023-02-06T11:02:50Z","timestamp":1675681370000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["CASPR2 antibody associated neurological syndromes in children"],"prefix":"10.1038","volume":"13","author":[{"given":"Liwen","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Zhuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dejun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenghui","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,6]]},"reference":[{"issue":"3","key":"28268_CR1","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1111\/ejn.14081","volume":"48","author":"M Saint-Martin","year":"2018","unstructured":"Saint-Martin, M. et al. Contactin-associated protein-like 2, a protein of the neurexin family involved in several human diseases. Eur. J. Neurosci. 48(3), 1906\u20131923 (2018).","journal-title":"Eur. J. Neurosci."},{"issue":"5","key":"28268_CR2","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1212\/WNL.0000000000002917","volume":"87","author":"A van Sonderen","year":"2016","unstructured":"van Sonderen, A. et al. The clinical spectrurn of Caspr2 antibody-associated disease [J]. Neurology 87(5), 521\u2013528 (2016).","journal-title":"Neurology"},{"issue":"9","key":"28268_CR3","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1001\/jamaneurol.2016.1585","volume":"73","author":"B Joubert","year":"2016","unstructured":"Joubert, B. et al. Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures. JAMA Neurol. 73(9), 1115\u20131124. https:\/\/doi.org\/10.1001\/jamaneurol.2016.1585 (2016) (PMID: 27428927).","journal-title":"JAMA Neurol."},{"issue":"4","key":"28268_CR4","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00415-019-09686-2","volume":"267","author":"M Boyko","year":"2020","unstructured":"Boyko, M. et al. Systematic review of the clinical spectrum of CASPR2 antibody syndrome. J. Neurol. 267(4), 1137\u20131146 (2020).","journal-title":"J. Neurol."},{"key":"28268_CR5","doi-asserted-by":"publisher","first-page":"652864","DOI":"10.3389\/fimmu.2021.652864","volume":"12","author":"X Qin","year":"2021","unstructured":"Qin, X. et al. Clinical character of CASPR2 autoimmune encephalitis: A multiple center retrospective study. Front. Immunol. 12, 652864 (2021).","journal-title":"Front. Immunol."},{"issue":"3","key":"28268_CR6","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/ana.25310","volume":"84","author":"AS L\u2019opez-Chiriboga","year":"2018","unstructured":"L\u2019opez-Chiriboga, A. S. et al. LGI1 and CASPR2 neurological autoimmunity in children. Ann. Neurol. 84(3), 473\u2013480 (2018).","journal-title":"Ann. Neurol."},{"key":"28268_CR7","doi-asserted-by":"crossref","unstructured":"Dubey, D., Singh, J., Britton, J. W., et al. Predictive models in the diagnosis and treatment of autoimmune epilepsy. Epilepsia 58(7).","DOI":"10.1111\/epi.13797"},{"issue":"8","key":"28268_CR8","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1093\/cid\/cit458","volume":"57","author":"A Venkatesan","year":"2013","unstructured":"Venkatesan, A. et al. International encephalitis consortium. Case definitions, diagnostic algorithms, and priorities in encephalitis: Consensus statement of the international encephalitis consortium. Clin. Infect. Dis. 57(8), 1114\u20131128 (2013).","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"28268_CR9","doi-asserted-by":"publisher","first-page":"e663","DOI":"10.1212\/NXI.0000000000000663","volume":"7","author":"T Cellucci","year":"2020","unstructured":"Cellucci, T. et al. Clinical approach to the diagnosis of autoimmune encephalitis in the pediatric patient. Neurol. Neuroimmunol. Neuroinflamm. 7(2), e663 (2020).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"28268_CR10","doi-asserted-by":"publisher","first-page":"577084","DOI":"10.1016\/j.jneuroim.2019.577084","volume":"337","author":"R Kammeyer","year":"2019","unstructured":"Kammeyer, R. & Piquet, A. L. Multiple co-existing antibodies in autoimmune encephalitis: A case and review of the literature. J. Neuroimmunol. 337, 577084 (2019).","journal-title":"J. Neuroimmunol."},{"issue":"3","key":"28268_CR11","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1002\/ana.25310","volume":"84","author":"AS L\u00f3pez-Chiriboga","year":"2018","unstructured":"L\u00f3pez-Chiriboga, A. S. et al. LGI1 and CASPR2 neurological autoimmunity in children. Ann. Neurol. 84(3), 473\u2013480 (2018).","journal-title":"Ann. Neurol."},{"key":"28268_CR12","doi-asserted-by":"publisher","first-page":"577008","DOI":"10.1016\/j.jneuroim.2019.577008","volume":"335","author":"M Nosadini","year":"2019","unstructured":"Nosadini, M. et al. LGI1 and CASPR2 autoimmunity in children: Systematic literature review and report of a young girl with Morvan syndrome. J. Neuroimmunol. 335, 577008 (2019).","journal-title":"J. Neuroimmunol."},{"key":"28268_CR13","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/ene.13180","volume":"24","author":"CG Bien","year":"2017","unstructured":"Bien, C. G. et al. Anti-contactin-associated protein-2 encephalitis: Relevance of antibody titres, presentation and outcome. Eur. J. Neurol. 24, 175\u2013186 (2017).","journal-title":"Eur. J. Neurol."},{"key":"28268_CR14","doi-asserted-by":"publisher","first-page":"736035","DOI":"10.3389\/fped.2021.736035","volume":"9","author":"C Tan","year":"2021","unstructured":"Tan, C. et al. Clinical features and outcomes in pediatric autoimmune encephalitis associated with CASPR2 antibody. Front. Pediatr. 9, 736035 (2021).","journal-title":"Front. Pediatr."},{"key":"28268_CR15","doi-asserted-by":"publisher","first-page":"102011","DOI":"10.1016\/j.msard.2020.102011","volume":"41","author":"T Foiadelli","year":"2020","unstructured":"Foiadelli, T. et al. Seizures and myelin oligodendrocyte glycoprotein (MOG) antibodies: Two paradigmatic cases and a review of the literature. Mult. Scler. Relat. Disord. 41, 102011 (2020).","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"28268_CR16","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s13311-019-00750-3","volume":"16","author":"KS Husari","year":"2019","unstructured":"Husari, K. S. & Dubey, D. Autoimmune epilepsy. Neurotherapeutics 16(3), 685\u2013702 (2019).","journal-title":"Neurotherapeutics"},{"key":"28268_CR17","doi-asserted-by":"crossref","first-page":"178","DOI":"10.4103\/aian.AIAN_574_20","volume":"24","author":"S Shivaram","year":"2021","unstructured":"Shivaram, S. et al. Clinical profile and treatment response in patients with CASPR2 antibody-associated neurological disease. Annals Indian Acad Neurol. 24, 178\u2013185 (2021).","journal-title":"Annals Indian Acad Neurol."},{"key":"28268_CR18","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.eplepsyres.2016.12.010","volume":"129","author":"M Carre\u00f1o","year":"2017","unstructured":"Carre\u00f1o, M. et al. Epilepsy surgery in drug resistant temporal lobe epilepsy associated with neuronal antibodies. Epilepsy Res. 129, 101\u2013105 (2017).","journal-title":"Epilepsy Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28268-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28268-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28268-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,6]],"date-time":"2023-12-06T08:16:40Z","timestamp":1701850600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-28268-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,6]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["28268"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-28268-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,6]]},"assertion":[{"value":"10 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2073"}}